Las Vegas—Findings from a study of 128 patients with spontaneous intracranial hemorrhage (ICrH) receiving a factor Xa (FXa) inhibitor found that andexanet alfa (Andexxa, Portola) halted bleeding in 79% of patients within 12 hours of administration. The results were presented at the ASHP 2019 Midyear Clinical Meeting (poster 8-054).
DECEMBER 12, 2019